Cristina Csimma

Palisade Bio

Palisade Bio is advancing a new category of medicines with a novel mechanism of action that may revolutionize the standard of care by protecting patients against potentially debilitating GI complications before they can arise during surgery. We base these treatments on sound science and therapies with a decades-long history of safe and effective usage. Gastrointestinal (GI) complications are a risk during and after surgery due to digestive enzymes (proteases) escaping patients' intestines. Proteases can damage the intestines and surrounding tissue causing them to stop working normally. This can lead to a debilitating form of constipation (ileus) and abdominal scarring (adhesions) that can cause life-long problems such as infertility or require additional corrective surgeries and medications. Preventing or reducing ileus and adhesions with a convenient oral treatment could greatly simplify the surgical experience for millions, reducing their length of hospital stay and need to more surgeries. We designed our lead late-stage clinical asset (LB1148) to protect against debilitating postoperative constipation (ileus) and reduce the scarring (adhesion) incidence. Its development may pave the way for additional protease inhibitor therapies to treat a range of GI conditions. Our leadership embodies our future-facing vision. Armed with extensive experience, we refuse to compromise as we seek to bring forth a new standard of care. Our team boasts over 15 years of expertise developing protease inhibitors that is backed by clinical prowess across all development stages, from R&D through approval.